Advertisement

Advertisement

11th European Breast Cancer Conference

breast cancer

EBCC-11: Mastectomy and Axillary Dissection and Neoadjuvant Targeted Treatment in HER2-Positive Breast Cancer

Extensive surgery involving mastectomy and removal of several lymph nodes may be safely avoided for more women with some types of breast cancer if they receive targeted drugs before surgery, according...

breast cancer

EBCC-11: Women Report Fewer Side Effects With Partial or Reduced Breast Radiotherapy vs Standard WBRT

The average number of moderate or marked side effects reported by patients with breast cancer is lower if they are treated with radiotherapy to part of the breast or a reduced dose to the whole breast...

breast cancer

EBCC-11: MINDACT Trial: Patients With Early Breast Cancer and Risk of Locoregional Recurrence

Women with small, low-grade, well-defined breast tumors and a genetic profile that shows they are at low risk of the cancer metastasizing have only a 1.4% risk of locoregional recurrence within 5 year...

breast cancer

EBCC-11: Sentinel Lymph Node Biopsy in Triple-Negative and HER2-Positive Breast Cancers

Sentinel lymph node biopsies may be safely avoided for some women, according to research presented at the 11th European Breast Cancer Conference (EBCC-11). Two new studies show that women with either ...

breast cancer

EBCC-11: Double Mastectomy in BRCA1 and BRCA2 Carriers

Healthy women who carry a breast cancer–causing mutation in the BRCA1 gene not only reduce their risk of developing the disease but also their chances of dying from it if they have both breasts ...

breast cancer

EBCC-11: DCIS Less Likely to Recur in Patients Who Are Postmenopausal, ER-Positive

Patients with ductal carcinoma in situ (DCIS) are less likely to have recurrent disease if they are postmenopausal or if their tumor is estrogen receptor (ER)-positive, according to research presented...

breast cancer

EBCC-11: Risk of a Second Breast Cancer Can Be Better Quantified in Patients With a BRCA Mutation

The risk of a second breast cancer in patients with high-risk BRCA gene mutations can be more precisely predicted by testing for several other genetic variants, each of which are known to have a small...

Advertisement

Advertisement




Advertisement